A5032598117- Monoclonal and Polyclonal Antibodies Research
- T-cell and B-cell Immunology
- HIV Research and Treatment
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Advanced Breast Cancer Therapies
- Viral-associated cancers and disorders
- vaccines and immunoinformatics approaches
- Genomic variations and chromosomal abnormalities
Harvard University
2019-2024
Dana-Farber Cancer Institute
2020-2024
Boston Children's Hospital
2019-2021
Howard Hughes Medical Institute
2019-2020
Engineering better bnAbs A highly effective HIV vaccine has been the goal of vaccinologists for nearly 35 years. successful would need to induce broadly neutralizing antibodies (bnAbs) that are capable multiple strains (see Perspective by Agazio and Torres). Steichen et al. report a strategy in which first shot can lead immune responses generate desired bnAbs. By combining knowledge human antibody repertoires structure guide design, they validated candidate immunogens through functional...
HIV-1 vaccine development aims to elicit broadly neutralizing antibodies (bnAbs) against diverse viral strains. In some HIV-1-infected individuals, bnAbs evolved from precursor through affinity maturation. To induce bnAbs, a must mediate similar antibody maturation process. One way test is immunize mouse models that express human bnAb precursors and assess whether the can convert into bnAbs. A major problem with such expression often hinders B cell development. Such developmental blocks may...
Significance The immune system can produce enormous varieties of antibodies to counter infections. In this study, we devised a method harness the power therapeutic antibodies. We used generate against human PD1, negative regulator T cell activity. Available anti-PD1 inhibit function thereby boosting activity tumor cells. diversified one such antibody and obtained multiple antibodies, some which stimulate, rather than inhibit, PD1 in vitro. Such PD1-stimulatory could potentially be suppress...
Abstract HIV-1 vaccine development aims to elicit broadly neutralizing antibodies (bnAbs) against diverse viral strains. In some infected individuals, bnAbs evolve from precursor through affinity maturation. To induce bnAbs, a must mediate similar process of antibody One way test vaccination strategies is immunize mouse models that express human bnAb precursors. Such immunization experiments can assess whether the convert into bnAb. A major problem with such expression often hinders B cell...
Abstract V(D)J recombination generates mature B cells that express huge repertoires of primary antibodies as diverse immunoglobulin heavy (IgH) and light chains (IgL) their cell antigen receptors (BCRs). Cognate binding to BCR variable region domains activates into the germinal center (GC) reaction in which somatic hypermutation (SHM) modifies region-encoding sequences, with subsequent selection for mutations improve antigen-binding affinity, ultimately leading antibody affinity maturation....